US HB990 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on February 6 2019 - 25% progression, died in committee
Action: 2019-02-06 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 6 2019 - 25% progression, died in committee
Action: 2019-02-06 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.
Title
Hatch-Waxman Integrity Act of 2019
Sponsors
Rep. Bill Flores [R-TX] |
History
Date | Chamber | Action |
---|---|---|
2019-02-06 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-02-06 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-02-06 | House | Introduced in House |
Same As/Similar To
SB344 (Same As) 2019-02-06 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Administrative remedies
Drug safety, medical device, and laboratory regulation
Fraud offenses and financial crimes
Health
Intellectual property
Licensing and registrations
Prescription drugs
Securities
Drug safety, medical device, and laboratory regulation
Fraud offenses and financial crimes
Health
Intellectual property
Licensing and registrations
Prescription drugs
Securities
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/990/all-info |
Text | https://www.congress.gov/116/bills/hr990/BILLS-116hr990ih.pdf |